Stronger Compounding, Stronger Savings.
We’re a Group Purchasing Organization dedicated to compounding pharmacies, securing the best prices on high-quality APIs. By pooling our members’ buying power, we deliver compounding savings that grow with every order.
who we Serve
At CPNRX, we partner with 503B outsourcing facilities to deliver high-quality Active Pharmaceutical Ingredients (APIs) and innovative compounding solutions as your dedicated Group Purchasing Organization (GPO). Our goal is to support your ability to produce sterile and non-sterile medications at scale, ensuring compliance with Section 503B of the Federal Food, Drug, and Cosmetic Act while meeting the demands of healthcare providers and patients.
Section 503B outsourcing facilities are uniquely positioned to supply compounded drugs for office use, requiring a reliable source of APIs that adhere to stringent cGMP standards. CPNRX ensures you have access to APIs that meet these requirements—whether they align with United States Pharmacopeia (USP) or National Formulary (NF) monographs, are components of FDA-approved drugs, or are approved under the FDA’s 503B bulks list. Our GPO framework provides cost-effective procurement, allowing you to maintain efficiency and quality in your large-scale compounding operations.
There are many small pharma companies that have made significant discoveries in drug molecules. They may have identified new compounds with promising activity against particular health targets. Both emerging and virtual pharma companies play a vital role in the pharmaceutical industry by driving innovation and bringing new drugs to market. They are agile and can move quickly from discovery to proof-of-concept, which is essential for the fast-paced nature of medical advancements. However, they often face challenges due to limited resources and expertise in drug formulation, which is crucial for advancing their discoveries to the clinical trial phase. If this is your company, Renejix can help. We provide pre-formulation data package development, API assessments, drug characterization formulation development, small-scale formulations for conducting toxicology studies and initial in-vivo animal studies, and assessment of likely formulation development options for first in man trials, phase I-III, and commercial manufacturing.
Our Leadership
Our team is working everyday to build a better compounding network & help ensure you get the best prices and savings.
Anjan K. Chatterji, MBA, J.D., LL.M CEO
Anjan Chatterji is a seasoned pharmaceutical portfolio expert with 25+ years of experience managing over $250 million in healthcare investments and structuring royalty agreements for 505(b)(2) and generic drugs. As Managing Partner and CEO of Wilson Chatterji Ventures, he has spearheaded commercialization strategies that drive sustainable ROI, accelerate market entry, and align R&D investments with growth opportunities.Anjan has advised pharmaceutical companies on scaling portfolios, navigating FDA/FTC regulations, and executing high-impact market strategies. A trusted industry leader, he has served on the boards of Oxeia Biopharma and Windgap Medical and played a key role in launching multiple 505(b)(2) drugs. His legal scholarship, cited in the U.S. Supreme Court’s FTC v. Actavis decision, underscores his deep influence on pharmaceutical legal frameworks and patent strategies. With a background as an economist and lawyer, Anjan has held executive roles in biopharma, medical technology, venture capital, and financial strategy. He previously led the Department of Healthcare Law & Economics at Foley & Lardner LLP in NY, providing expertise in patents, licensing, FDA regulatory strategies, and financial structuring. His work includes pioneering the first "At-Risk Launch" insurance policy and expert damages reporting in major industry cases.Specializing in M&A, patent strategy, licensing, and financial engineering, Anjan is a sought-after leader in corporate development, market forecasting, and healthcare economics. His ability to drive commercial success, structure innovative financial models, and navigate complex regulatory landscapes makes him an invaluable partner in the pharmaceutical and investment sectors.
Srinivas Maddali, RPh CBO
Dalbir Bains, BCom., CFA
Board Advisor
Vineeth Reddy, B.S., PMP
COO
Vineeth Reddy is an energetic pharmaceutical executive with a proven track record in wholesale, in-licensing, distribution, and manufacturing. He serves as an executive officer at Sanuscure Pharmaceuticals and IBG Drugs, two leading pharmaceutical distribution companies that supply the government, open markets, hospitals, pharmacies, and healthcare systems. Through these leadership roles, he has successfully expanded market access, optimized supply chain logistics, and strengthened partnerships with key industry stakeholders. With extensive experience in scaling pharmaceutical businesses, Vineeth has played a pivotal role in securing high-value in-licensing agreements, strengthening distribution networks, and driving commercial success. His expertise in market access, regulatory navigation, and commercialization strategy has enabled companies to maximize product reach and profitability in competitive markets.Vineeth has cultivated strong relationships with major pharmaceutical entities, leveraging his deep industry connections to facilitate strategic partnerships, negotiate competitive agreements, and drive sustainable growth. His ability to bridge technical expertise with commercial strategy makes him a trusted leader in pharmaceutical formulation, analytical sciences, manufacturing, and CMC (Chemistry, Manufacturing & Controls) systems.His leadership is defined by operational excellence, strategic vision, and a results-driven approach, ensuring that the pharmaceutical businesses he leads continue to thrive in an evolving healthcare landscape.
